This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Altintoprak, F., Dikicier, E., Deveci, U., Cakmak, G., Yalkin, O., Yucel, M., . . . Dilek, O. (2012). Intestinal obstruction due to bezoars: a retrospective clinical study. European Journal of Trauma & Emergency Surgery, 38(5), 569-575. doi:10.1007/s00068-012-0203-0AltintoprakF.DikicierE.DeveciU.CakmakG.YalkinO.YucelM., . . . DilekO. (2012). Intestinal obstruction due to bezoars: a retrospective clinical study. European Journal of Trauma & Emergency Surgery, 38(5), 569-575. doi:10.1007/s00068-012-0203-010.1007/s00068-012-0203-0Search in Google Scholar
Ao, P., Sebastianski, M., Selvarajah, V., & Gramlich, L. (2015). Comparison of Complication Rates, Types, and Average Tube Patency Between Jejunostomy Tubes and Percutaneous Gastrostomy Tubes in a Regional Home Enteral Nutrition Support Program. Nutrition in Clinical Practice, 30(3), 393.AoP.SebastianskiM.SelvarajahV., & GramlichL. (2015). Comparison of Complication Rates, Types, and Average Tube Patency Between Jejunostomy Tubes and Percutaneous Gastrostomy Tubes in a Regional Home Enteral Nutrition Support Program. Nutrition in Clinical Practice, 30(3), 393.10.1177/0884533614554263Search in Google Scholar
Bianco, G., Vuolo, G., Ulivelli, M., Bartalini, S., Chieca, R., Rossi, A., & Rossi, S. (2012). A clinically silent, but severe, duodenal complication of duodopa infusion. Journal of Neurology, Neurosurgery & Psychiatry, 83(6), 668-670.BiancoG.VuoloG.UlivelliM.BartaliniS.ChiecaR.RossiA., & RossiS. (2012). A clinically silent, but severe, duodenal complication of duodopa infusion. Journal of Neurology, Neurosurgery & Psychiatry, 83(6), 668-670.10.1136/jnnp-2011-301984Search in Google Scholar
Chang, F. C. F., Kwan, V., van der Poorten, D., Mahant, N., Wolfe, N., Ha, A. D., . . . Fung, V. S. C. (2016). Clinical Study: Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. Journal of Clinical Neuroscience, 25, 41-45. doi:10.1016/j.jocn.2015.05.059ChangF. C. F.KwanV.van der PoortenD.MahantN.WolfeN.HaA. D., . . . FungV. S. C. (2016). Clinical Study: Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease. Journal of Clinical Neuroscience, 25, 41-45. doi:10.1016/j.jocn.2015.05.05910.1016/j.jocn.2015.05.059Search in Google Scholar
Clarke, E., & Lewis, S. (2016). Low incidence of complications with Freka PEG tubes. Frontline Gastroenterology, 7(4), 332.ClarkeE., & LewisS. (2016). Low incidence of complications with Freka PEG tubes. Frontline Gastroenterology, 7(4), 332.10.1136/flgastro-2015-100645Search in Google Scholar
Dowman, J. K., Ditchburn, L., Chapman, W., Lidder, P., Wootton, N., Ryan, N., & Cooney, R. M. (2015). Observed high incidence of buried bumper syndrome associated with Freka PEG tubes. Frontline Gastroenterology, 6(3), 194.DowmanJ. K.DitchburnL.ChapmanW.LidderP.WoottonN.RyanN., & CooneyR. M. (2015). Observed high incidence of buried bumper syndrome associated with Freka PEG tubes. Frontline Gastroenterology, 6(3), 194.10.1136/flgastro-2014-100503Search in Google Scholar
Epstein, M., Johnson, D. A., Hawes, R., Schmulewitz, N., Vanagunas, A. D., Gossen, E. R., . . . Benesh, J. (2016). Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson’s Disease. Clinical And Translational Gastroenterology, 7, e159-e159. doi:10.1038/ctg.2016.19EpsteinM.JohnsonD. A.HawesR.SchmulewitzN.VanagunasA. D.GossenE. R., . . . BeneshJ. (2016). Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson’s Disease. Clinical And Translational Gastroenterology, 7, e159-e159. doi:10.1038/ctg.2016.1910.1038/ctg.2016.19Search in Google Scholar
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015). Review: Gastrointestinal dysfunction in Parkinson’s disease. The Lancet Neurology, 14, 625-639. doi:10.1016/S1474-00007-1FasanoA.VisanjiN. P.LiuL. W. C.LangA. E., & PfeifferR. F. (2015). Review: Gastrointestinal dysfunction in Parkinson’s disease. The Lancet Neurology, 14, 625-639. doi:10.1016/S1474-00007-110.1016/S1474-4422(15)00007-1Search in Google Scholar
Fernandez, H. H., Standaert, D. G., Hauser, R. A., Lang, A. E., Fung, V. S. C., Klostermann, F., . . . Espay, A. J. (2015). Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: Final 12-month, open-label results. Movement Disorders, 30(4), 500.FernandezH. H.StandaertD. G.HauserR. A.LangA. E.FungV. S. C.KlostermannF., . . . EspayA. J. (2015). Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: Final 12-month, open-label results. Movement Disorders, 30(4), 500.10.1002/mds.26123467497825545465Search in Google Scholar
Foltynie, T., Limousin, P., Magee, C., James, C., Webster, G. J. M., & Lees, A. J. (2013). Impact of duodopa on quality of life in advanced parkinson’s disease: A UK case series. Parkinson’s Disease. doi:10.1155/2013/362908FoltynieT.LimousinP.MageeC.JamesC.WebsterG. J. M., & LeesA. J. (2013). Impact of duodopa on quality of life in advanced parkinson’s disease: A UK case series. Parkinson’s Disease. doi:10.1155/2013/36290810.1155/2013/362908358648823476888Search in Google Scholar
Galletti, R., Sabet, D., Segre, O., Aimasso, U., Finocchiaro, E., Fadda, M., . . . Lopiano, L. (2011). Nutritional assessment in patients with Parkinson’s disease treated with duodenal infusion of L-dopa (preliminary data). Nutritional Therapy & Metabolism, 29(1), 47-50.GallettiR.SabetD.SegreO.AimassoU.FinocchiaroE.FaddaM., . . . LopianoL. (2011). Nutritional assessment in patients with Parkinson’s disease treated with duodenal infusion of L-dopa (preliminary data). Nutritional Therapy & Metabolism, 29(1), 47-50.Search in Google Scholar
Kimber, T. E., & Schoeman, M. (2014). Direct endoscopic jejunosotomy for the administration of levodopa-carbidopa intestinal gel in Parkinson’s disease. Parkinsonism & Related Disorders, 20(7), 786-788. doi:10.1016/j.parkreldis.2014.03.015KimberT. E., & SchoemanM. (2014). Direct endoscopic jejunosotomy for the administration of levodopa-carbidopa intestinal gel in Parkinson’s disease. Parkinsonism & Related Disorders, 20(7), 786-788. doi:10.1016/j.parkreldis.2014.03.01510.1016/j.parkreldis.2014.03.015Search in Google Scholar
Lang, A. E., Fasano, A., Rodriguez, R. L., Draganov, P. V., Boyd, J. T., Chouinard, S., . . . Dubow, J. (2016). Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Movement Disorders, 31(4), 538-546. doi:10.1002/mds.26485LangA. E.FasanoA.RodriguezR. L.DraganovP. V.BoydJ. T.ChouinardS., . . . DubowJ. (2016). Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Movement Disorders, 31(4), 538-546. doi:10.1002/mds.2648510.1002/mds.26485Search in Google Scholar
Negreanu, M. L., Popescu, B. O., Babiuc, R. D., Ene, A., Andronescu, D., & Băjenaru, R. D. (2010). Cutting the Gordian knot: the blockage of the jejunal tube, a rare complication of Duodopa infusion treatment. Journal of Medicine and Life, 3(2), 191-192.NegreanuM. L.PopescuB. O.BabiucR. D.EneA.AndronescuD., & BăjenaruR. D. (2010). Cutting the Gordian knot: the blockage of the jejunal tube, a rare complication of Duodopa infusion treatment. Journal of Medicine and Life, 3(2), 191-192.Search in Google Scholar
Nyholm, D., Johansson, A., Aquilonius, S. M., Lewander, T., LeWitt, P. A., & Lundqvist, C. (2008). Enteral levodopa/carbidopa infusion in advanced Parkinson disease: Long-term exposure. Clinical Neuropharmacology, 31(2), 63-73. doi:10.1097/WNF.0b013e3180ed449fNyholmD.JohanssonA.AquiloniusS. M.LewanderT.LeWittP. A., & LundqvistC. (2008). Enteral levodopa/carbidopa infusion in advanced Parkinson disease: Long-term exposure. Clinical Neuropharmacology, 31(2), 63-73. doi:10.1097/WNF.0b013e3180ed449f10.1097/WNF.0b013e3180ed449fSearch in Google Scholar
Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., . . . Antonini, A. (2014). Articles: Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, 13, 141-149. doi:10.1016/S1474-4422(13)70293-XOlanowC. W.KieburtzK.OdinP.EspayA. J.StandaertD. G.FernandezH. H., . . . AntoniniA. (2014). Articles: Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, 13, 141-149. doi:10.1016/S1474-4422(13)70293-X10.1016/S1474-4422(13)70293-XSearch in Google Scholar
Panagiotakis, P. H., DiSario, J. A., Hilden, K., Ogara, M., & Fang, J. C. (2008). DPEJ Tube Placement Prevents Aspiration Pneumonia in High-Risk Patients. Nutrition in Clinical Practice, 23(2), 172.PanagiotakisP. H.DiSarioJ. A.HildenK.OgaraM., & FangJ. C. (2008). DPEJ Tube Placement Prevents Aspiration Pneumonia in High-Risk Patients. Nutrition in Clinical Practice, 23(2), 172.10.1177/088453360831453718390785Search in Google Scholar
Santos García, D., Martínez Castrillo, J. C., Puente Périz, V., Seoane Urgorri, A., Fernández Díez, S., Benita León, V., . . . Mariscal Pérez, N. (2016). Clinical management of patients with advanced Parkinson’s disease treated with continuous intestinal infusion of levodopa/carbidopa. Neurodegenerative Disease Management, 6(3), 187.Santos GarcíaD.Martínez CastrilloJ. C.Puente PérizV.Seoane UrgorriA.Fernández DíezS.Benita LeónV., . . . Mariscal PérezN. (2016). Clinical management of patients with advanced Parkinson’s disease treated with continuous intestinal infusion of levodopa/carbidopa. Neurodegenerative Disease Management, 6(3), 187.10.2217/nmt-2016-001127075968Search in Google Scholar
Senek, M., & Nyholm, D. (2014). Continuous Drug Delivery in Parkinson’s Disease. CNS Drugs, 28(1), 19-27.SenekM., & NyholmD. (2014). Continuous Drug Delivery in Parkinson’s Disease. CNS Drugs, 28(1), 19-27.10.1007/s40263-013-0127-124323838Search in Google Scholar
Stathis, P., Tzias, V., Argyris, P., Barla, G., & Maltezou, M. (2014). Gastric bezoar complication of Duodopa® therapy in Parkinson’s disease, treated with Coca‐Cola®. Movement Disorders, 29(8), 1087-1088. doi:10.1002/mds.25930StathisP.TziasV.ArgyrisP.BarlaG., & MaltezouM. (2014). Gastric bezoar complication of Duodopa® therapy in Parkinson’s disease, treated with Coca‐Cola®. Movement Disorders, 29(8), 1087-1088. doi:10.1002/mds.2593010.1002/mds.2593024909683Search in Google Scholar
Tsui, D. S.-Y. (2014). The Tomorrow: Advanced Treatments in Parkinson’s Disease Does Not Necessarily Equate to Treatments in Advanced Parkinson’s Disease. Australasian Journal of Neuroscience, 24(2), 34.TsuiD. S.-Y. (2014). The Tomorrow: Advanced Treatments in Parkinson’s Disease Does Not Necessarily Equate to Treatments in Advanced Parkinson’s Disease. Australasian Journal of Neuroscience, 24(2), 34.Search in Google Scholar
van Laar, T., Nyholm, D., & Nyman, R. (2016). Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson’s disease. Acta Neurologica Scandinavica, 133(3), 208-215. doi:10.1111/ane.12464van LaarT.NyholmD., & NymanR. (2016). Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson’s disease. Acta Neurologica Scandinavica, 133(3), 208-215. doi:10.1111/ane.1246410.1111/ane.1246426213103Search in Google Scholar
Vuolo, G., Gaggelli, I., Tirone, A., Varrone, F., Rennenkappf, S., Chieca, R., . . . Di Cosmo, L. (2012). Fistulization and bowel perforation by J-PEG in a parkinsonian patient treated with continuous infusion of Duodopa®. Nutritional Therapy & Metabolism, 30(2), 95-97.VuoloG.GaggelliI.TironeA.VarroneF.RennenkappfS.ChiecaR., . . . Di CosmoL. (2012). Fistulization and bowel perforation by J-PEG in a parkinsonian patient treated with continuous infusion of Duodopa®. Nutritional Therapy & Metabolism, 30(2), 95-97.Search in Google Scholar
Zibetti, M., Merola, A., Artusi, C. A., Rizzi, L., Angrisano, S., Reggio, D., . . . Lopiano, L. (2014). Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. European Journal of Neurology, 21(2), 312.ZibettiM.MerolaA.ArtusiC. A.RizziL.AngrisanoS.ReggioD., . . . LopianoL. (2014). Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. European Journal of Neurology, 21(2), 312.10.1111/ene.1230924313838Search in Google Scholar
